title: Predictors of AMD treatment response.
authors.forename: Sanjeewa S
authors.initials: SS
authors.lastname: Wickremasinghe
authors.forename: Sukhpal S
authors.initials: SS
authors.lastname: Sandhu
authors.forename: Lucy
authors.initials: L
authors.lastname: Busija
authors.forename: Jonathan
authors.initials: J
authors.lastname: Lim
authors.forename: Devinder S
authors.initials: DS
authors.lastname: Chauhan
authors.forename: Robyn H
authors.initials: RH
authors.lastname: Guymer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D000069579:Ranibizumab; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab